GCG and Parkinson disease: Overall, EcN-GLP-1 demonstrated significant anti-inflammatory effects in both the colon and the substantia nigra, and created a CNS immune microenvironment unfavourable to microglial M1 phenotype, improving PD neuropathology and outcome.